211 related articles for article (PubMed ID: 25764167)
1. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.
Liu J; Jiang W; Mao K; An Y; Su F; Kim BY; Liu Q; Jacobs LK
Breast Cancer Res Treat; 2015 Apr; 150(2):439-45. PubMed ID: 25764167
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
[TBL] [Abstract][Full Text] [Related]
3. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
Liu Y; West R; Weber JD; Colditz GA
Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
[TBL] [Abstract][Full Text] [Related]
4. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
Brown M; Bauer K; Pare M
Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
[TBL] [Abstract][Full Text] [Related]
5. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.
Mezencev R; Švajdler M
Breast Cancer; 2017 May; 24(3):400-410. PubMed ID: 27502779
[TBL] [Abstract][Full Text] [Related]
6. Second primary breast cancer occurrence according to hormone receptor status.
Kurian AW; McClure LA; John EM; Horn-Ross PL; Ford JM; Clarke CA
J Natl Cancer Inst; 2009 Aug; 101(15):1058-65. PubMed ID: 19590058
[TBL] [Abstract][Full Text] [Related]
7. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
8. Trends in use of contralateral prophylactic mastectomy by racial/ethnic group and ER/PR status among patients with breast cancer: A SEER population-based study.
Brown D; Shao S; Jatoi I; Shriver CD; Zhu K
Cancer Epidemiol; 2016 Jun; 42():24-31. PubMed ID: 26999400
[TBL] [Abstract][Full Text] [Related]
9. The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status.
Schonfeld SJ; Curtis RE; Anderson WF; Berrington de González A
Cancer Causes Control; 2012 Oct; 23(10):1721-8. PubMed ID: 22918549
[TBL] [Abstract][Full Text] [Related]
10. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
11. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database.
Anderson WF; Chu KC; Chatterjee N; Brawley O; Brinton LA
J Clin Oncol; 2001 Jan; 19(1):18-27. PubMed ID: 11134191
[TBL] [Abstract][Full Text] [Related]
12. Young premenopausal women with breast cancer, especially estrogen receptor negative, are at significantly increased risk for subsequent ovarian cancer.
Lehrer S; Rheinstein PH; Green S; Rosenzweig KE
Discov Med; 2016 Oct; 22(121):209-213. PubMed ID: 27875672
[TBL] [Abstract][Full Text] [Related]
13. Declining second primary ovarian cancer after first primary breast cancer.
Schonfeld SJ; Berrington de Gonzalez A; Visvanathan K; Pfeiffer RM; Anderson WF
J Clin Oncol; 2013 Feb; 31(6):738-43. PubMed ID: 23284037
[TBL] [Abstract][Full Text] [Related]
14. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage.
Chen L; Linden HM; Anderson BO; Li CI
Breast Cancer Res Treat; 2014 Oct; 147(3):609-16. PubMed ID: 25164974
[TBL] [Abstract][Full Text] [Related]
15. Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis of epidemiological studies.
Suzuki R; Orsini N; Mignone L; Saji S; Wolk A
Int J Cancer; 2008 Apr; 122(8):1832-41. PubMed ID: 18067133
[TBL] [Abstract][Full Text] [Related]
16. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there?
Potter JD; Cerhan JR; Sellers TA; McGovern PG; Drinkard C; Kushi LR; Folsom AR
Cancer Epidemiol Biomarkers Prev; 1995 Jun; 4(4):319-26. PubMed ID: 7655325
[TBL] [Abstract][Full Text] [Related]
17. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
18. Dietary fiber intake and risk of postmenopausal breast cancer defined by estrogen and progesterone receptor status--a prospective cohort study among Swedish women.
Suzuki R; Rylander-Rudqvist T; Ye W; Saji S; Adlercreutz H; Wolk A
Int J Cancer; 2008 Jan; 122(2):403-12. PubMed ID: 17764112
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
20. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status--the Japan public health center-based prospective study.
Suzuki R; Iwasaki M; Inoue M; Sasazuki S; Sawada N; Yamaji T; Shimazu T; Tsugane S;
Int J Cancer; 2011 Sep; 129(5):1214-24. PubMed ID: 21064092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
